- |||||||||| ecubectedin (PM14) / PharmaMar, PM54 / PharmaMar
Ecubectedin and PM54 demonstrate antitumor activity in patient-derived xenograft models of soft tissue sarcoma (Section 22) - Mar 5, 2024 - Abstract #AACR2024AACR_3941;
Xenografted mice were randomized to six treatment groups: 1) vehicle (VEH) (5% dextrose) 5 mL/kg once weekly (QW) intravenously (IV); 2) DOX 5 mg/kg QW IV; 3) trabectedin (TRA) 0.15 mg/kg QW IV; 4) LUR 0.18 mg/kg QW IV; 5) ECU 1.2 mg/kg QW IV; 6) PM54 1.2 mg/kg QW IV... Novel drugs exhibit promising results in the PDX models tested, supporting ongoing exploration in additional PDX models of synovial sarcoma and dedifferentiated liposarcoma.
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
A phase III study of lurbinectedin alone or in combination with irinotecan vs (On Demand | Hall A; Poster Bd # 233a) - Apr 26, 2023 - Abstract #ASCO2023ASCO_1999;
P1/2, P2,
Novel drugs exhibit promising results in the PDX models tested, supporting ongoing exploration in additional PDX models of synovial sarcoma and dedifferentiated liposarcoma. Main exclusion criteria include platinum-na
- |||||||||| ecubectedin (PM14) / PharmaMar
Ecubectedin is a novel transcriptional inhibitor that displays potent antitumor effects in vitro and in vivo (Section 17; Poster Board #12) - Mar 14, 2023 - Abstract #AACR2023AACR_3868;
Background - Ecubectedin (PM14) is a novel transcriptional inhibitor related to ecteinascidins family...In mice bearing MDA-MB-231, H526 and 22Rv1 tumors, complete tumor remissions were seen in 1/10 (lasting 103 days), 9/10 (lasting 220 days) and 7/10 (lasting 13 days) ecubectedin-treated animals, respectively.Conclusions - Ecubectedin is a novel transcriptional inhibitor that displays potent antiproliferative activity in different human solid cancer models in vitro and in vivo. The drug is currently in clinical development in Phase II trials.
- |||||||||| PM14 / PharmaMar
Journal: First report of peach leaf pitting-associated virus (PLPaV), plum bark necrosis stem pitting-associated virus (PBNSPaV), and mume virus A (MuVA) from Mei (Prunus mume) in China. (Pubmed Central) - Feb 9, 2021
2020) with 92.30% of sequence identity; the scalffold of MuVA (MW217572) covered 14.50% of the genome of the isolate pm14 from Japan (NC 040568.1) (Marais et al.2018) with 98.47% sequence identity; the scaffold of PLPaV (MW217573) covered 15.26% of the genome of the isolate XJ-6 from peach (KY867750.1) (He et al...Although it is difficult to link a particular virus with the observed symptoms due to mixed infections, the symptoms were significantly associated with viral infection because almost all symptomatic leaf samples were virus(es)-positive. Further studies would be required to determine the distribution and impact of these viruses on mei trees and other stone fruits species and to understand the possibility that mei trees may play a role in PLPaV epidemiology.
- |||||||||| PM14 / PharmaMar
Journal: Deciphering metal toxicity responses of flax (Linum usitatissimum L.) with exopolysaccharide and ACC-deaminase producing bacteria in industrially contaminated soils. (Pubmed Central) - May 16, 2020
gibsonii PM11 and B. xiamenensis PM14 in metal phytoremediation of metals, their survival and plant growth promotion potential in metal polluted environment as well as alterations in physio-biochemical responses of inoculated L. usitatissimum plants towards heavy metal toxicity...In current study, inoculation of IAA, EPS and ACC-deaminase producing bacteria enhances plant growth and nutrient availability by minimizing metal-induced stressed conditions. Moreover, elevated phytoextraction of multi-metals from industrial contaminated soils by PGPR inoculated L. usitatissimum plants reveal that these strains could be used as sweepers in heavy metals polluted environment.
- |||||||||| PM14 / PharmaMar
Journal: Identification and characterization of a carboxypeptidase N1 from red lip mullet (Liza haematocheila); revealing its immune relevance. (Pubmed Central) - Mar 25, 2019
...In silico analysis discovered two domains of PM14-Zn carboxypeptidase and a C-terminal domain of M14 N/E carboxypeptidase, two zinc-binding signature motifs, and an N-glycosylation site in the MuCPN1 sequence...MuCPN1 transfected cells triggered a 2.2-fold increase of nitric oxide (NO) production upon LPS stimulation compared to the un-transfected controls suggesting that MuCPN1 is an active protease which releases arginine from complement C3a, C4a, and C5a. These results have driven certain way towards enhancing the understanding of immune role of MuCPN1 in the complement defense mechanism of red lip mullet.
|
